Speaker Profile
Ph.D., Distinguished Scientist, Vice President Corporate Affairs, GRAIL
Biography
Dr. Megan P. Hall partners cross-functionally with Medical Affairs, Corporate Communications, Government Affairs, Investor Relations, and various scientific and clinical teams to develop and execute company-wide initiatives supporting GRAILs product portfolio. Dr. Hall also established and built GRAILs Medical Affairs group, supporting the development and launch of Galleri, a blood-based multi-cancer early detection test. Previously, Dr. Hall was Director of Medical Communications at Jazz Pharmaceuticals and Natera, and was an editor at the flagship open-access journal, PLOS Biology. She also held various research roles funded by the American Heart Association, California Institute of Regenerative Medicine, National Institutes of Health, and the Howard Hughes Research Foundation. She earned a BS in Biological Sciences from the UC-Santa Barbara, and a PhD in Microbiology, Immunology, and Molecular Genetics from the UC-Los Angeles.
Talk
Multi-Cancer Early Detection: Innovation for Population Health
GRAIL uses next-generation sequencing, population-scale clinical studies, and state-of-the-art computer and data science to detect cancer early when it can be cured. Learn how our multi-cancer early detection technology can improve cancer detection on a population scale, and how our methylation-based platform has applications across the cancer care continuum.
Clinical Dx Showcase:
GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
